These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39010815)

  • 1. Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real-world setting in Taiwan.
    Chen KH; Li KJ; Fang YF; Hsieh SC; Chen YC; Lee CS; Luo SF; Cheng TT; Tsai WC; Lo YC; Lan JL
    Int J Rheum Dis; 2024 Jul; 27(7):e15199. PubMed ID: 39010815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
    BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
    Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
    Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
    Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
    Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
    Galeazzi M; Alten R; Chartier M; Elbez Y; Fusaro E; Le Bars M; Lorenz HM; Pagano Mariano G; Muratore M; Nüßlein HG; Patanè G
    Clin Exp Rheumatol; 2018; 36(5):935-936. PubMed ID: 29600933
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
    Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
    Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
    Westhovens R; Connolly SE; Margaux J; Vanden Berghe M; Maertens M; Van den Berghe M; Elbez Y; Chartier M; Baeke F; Robert S; Malaise M
    Rheumatol Int; 2020 Sep; 40(9):1409-1421. PubMed ID: 32556473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Peichl P; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
    Clin Exp Rheumatol; 2016; 34(3):489-99. PubMed ID: 26966919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
    Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
    Suissa S; Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P
    Semin Arthritis Rheum; 2019 Dec; 49(3):366-372. PubMed ID: 30979397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes among patients with early rapidly progressive rheumatoid arthritis.
    Klink AJ; Curtice TG; Gupta K; Tuell KW; Szymialis AR; Nero D; Feinberg BA
    Am J Manag Care; 2019 Oct; 25(10):e288-e295. PubMed ID: 31622068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.
    Cagnotto G; Willim M; Nilsson JÅ; Compagno M; Jacobsson LTH; Saevarsdottir S; Turesson C
    Arthritis Res Ther; 2020 Jan; 22(1):15. PubMed ID: 31969172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
    BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
    Iannone F; Courvoisier DS; Gottenberg JE; Hernandez MV; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Choquette D; Finckh A
    Clin Rheumatol; 2017 Apr; 36(4):773-779. PubMed ID: 27966068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
    Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
    Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.